Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.97
Vitro Biopharma, Inc. incurred convertible notes of $375,000 aggregate principal amount, issued at $300,000 with 20% original issue discount with accredited investors at 20% per annum, accruing from earlier of maturity date or event of default, due f maturing May 16, 2024, extendable to August 16, 2024; or earlier upon a Liquidity Event.
- Instrument
- convertible notes
- Principal
- $375,000 aggregate principal amount, issued at $300,000 with 20% original issue discount
- Counterparty
- accredited investors
- Rate
- 20% per annum, accruing from earlier of maturity date or event of default, due f
- Maturity
- May 16, 2024, extendable to August 16, 2024; or earlier upon a Liquidity Event
- Event
- incurrence
Exact text from the filing
On May 13, 2024, Vitro BioPharma, Inc. (the “Company”) issued and sold to accredited investors, in a private placement, (i) senior secured convertible notes (the “Notes”) in the aggregate principal amount of $375,000, for an aggregate purchase price of $300,000 (reflecting a 20% original issue discount), and warrants to purchase shares of common stock of the Company (the “Warrants”), pursuant to a previously disclosed securities purchase agreement, dated November 16, 2023.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Vitro Biopharma, Inc. entered into senior secured convertible notes with accredited investors valued at aggregate principal amount of $375,000 (effective 2024-05-13).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- accredited investors
- Value
- aggregate principal amount of $375,000
- Effective
- 2024-05-13
Exact text from the filing
On May 13, 2024, Vitro BioPharma, Inc. (the “Company”) issued and sold to accredited investors, in a private placement, (i) senior secured convertible notes (the “Notes”) in the aggregate principal amount of $375,000
View on SEC.gov